Allotera Therapeutics
Clinical-stage developer of off-the-shelf CAR-T cell therapies, including Sofi-cel for aggressive T-cell cancers.
$35MSeries C extension and venture debt
ParticipantBC
Blood Cancer United's Therapy Acceleration Program
Activity from announced rounds
Activity in this selectionnomura-real-estate-development-co-f095adde
- Rounds participated in
- 2
- Confirmed lead rounds
- 0 1 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $112M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionCrossbow Therapeutics
Develops a novel class of potent and precise antibody therapies to treat a broad range of cancers
$77MSeries B
Role not disclosed